-

Shareholder Alert: Robbins LLP Announces It Is Investigating Grand Canyon Education, Inc. (LOPE) for Misleading Shareholders

SAN DIEGO & PHOENIX--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Grand Canyon Education, Inc. (NASDAQ: LOPE) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Grand Canyon provides education services to colleges and universities in the United States.

If you suffered a loss as a result of Grand Canyon's misconduct, click here.

Grand Canyon Education, Inc. (LOPE) Artificially Inflates its Profitability

In July 2018, Grand Canyon spun-off of its education assets through a sale to non-profit entity, Grand Canyon University ("GCU"). Following this spin-off, Grand Canyon consistently touted growth in net income and adjusted EBITDA. However, on September 9, 2019, Citron Research published a report revealing that it believed Grand Canyon "[had been] stuffing GCU with expenses to inflate its own profitability and as a result bankrupting GCU." About two months later, Grand Canyon announced its application for GCU's designation as a non-profit had been denied by the U.S Department of Education ("DOE"). Then, on January 28, 2020, Citron Research expanded on the DOE's findings, stating that Grand Canyon was the "educational Enron" that used its non-reporting subsidiary to "dump expenses and liabilities, while receiving a disproportionate amount of revenue at inflated margins…to artificially inflate the stock price." Following these disclosures, Grand Canyon's stock price fell $30.40, or 26%, to close at $84.07 per share on January 28, 2020.

Grand Canyon Education, Inc. (LOPE) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Grand Canyon settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom